Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 5
2003 3
2004 8
2005 4
2006 1
2007 5
2008 3
2009 4
2010 4
2011 6
2012 7
2013 4
2014 5
2015 4
2016 4
2017 2
2018 3
2019 2
2020 1
2021 3
2022 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

74 results

Results by year

Filters applied: . Clear all
Page 1
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.
Jacobson CA, Chavez JC, Sehgal AR, William BM, Munoz J, Salles G, Munshi PN, Casulo C, Maloney DG, de Vos S, Reshef R, Leslie LA, Yakoub-Agha I, Oluwole OO, Fung HCH, Rosenblatt J, Rossi JM, Goyal L, Plaks V, Yang Y, Vezan R, Avanzi MP, Neelapu SS. Jacobson CA, et al. Among authors: rosenblatt j. Lancet Oncol. 2022 Jan;23(1):91-103. doi: 10.1016/S1470-2045(21)00591-X. Epub 2021 Dec 8. Lancet Oncol. 2022. PMID: 34895487 Clinical Trial.
Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5).
Neelapu SS, Chavez JC, Sehgal AR, Epperla N, Ulrickson M, Bachy E, Munshi PN, Casulo C, Maloney DG, de Vos S, Reshef R, Leslie LA, Oluwole OO, Yakoub-Agha I, Khanal R, Rosenblatt J, Korn R, Peng W, Lui C, Wulff J, Shen R, Poddar S, Jung AS, Miao H, Beygi S, Jacobson CA. Neelapu SS, et al. Among authors: rosenblatt j. Blood. 2024 Feb 8;143(6):496-506. doi: 10.1182/blood.2023021243. Blood. 2024. PMID: 37879047 Free PMC article.
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.
Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S, Forero-Torres A, Moskowitz CH, Connors JM, Engert A, Larsen EK, Kennedy DA, Sievers EL, Chen R. Younes A, et al. Among authors: rosenblatt jd. J Clin Oncol. 2012 Jun 20;30(18):2183-9. doi: 10.1200/JCO.2011.38.0410. Epub 2012 Mar 26. J Clin Oncol. 2012. PMID: 22454421 Free PMC article. Clinical Trial.
Regulatory B cells in anti-tumor immunity.
Zhang Y, Gallastegui N, Rosenblatt JD. Zhang Y, et al. Among authors: rosenblatt jd. Int Immunol. 2015 Oct;27(10):521-30. doi: 10.1093/intimm/dxv034. Epub 2015 May 20. Int Immunol. 2015. PMID: 25999597 Review.
CD30: an important new target in hematologic malignancies.
Deutsch YE, Tadmor T, Podack ER, Rosenblatt JD. Deutsch YE, et al. Among authors: rosenblatt jd. Leuk Lymphoma. 2011 Sep;52(9):1641-54. doi: 10.3109/10428194.2011.574761. Epub 2011 May 27. Leuk Lymphoma. 2011. PMID: 21619423 Review.
B cell regulation of anti-tumor immune response.
Zhang Y, Morgan R, Podack ER, Rosenblatt J. Zhang Y, et al. Among authors: rosenblatt j. Immunol Res. 2013 Dec;57(1-3):115-24. doi: 10.1007/s12026-013-8472-1. Immunol Res. 2013. PMID: 24293009 Review.
Present and future of lung cancer vaccines.
Raez LE, Rosenblatt JD, Podack ER. Raez LE, et al. Among authors: rosenblatt jd. Expert Opin Emerg Drugs. 2006 Sep;11(3):445-59. doi: 10.1517/14728214.11.3.445. Expert Opin Emerg Drugs. 2006. PMID: 16939384 Review.
74 results